Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Treatment algorithm for palliative systemic therapy

Published bySucianty Setiabudi Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. Treatment algorithm for palliative systemic therapy"— Presentation transcript:

1 Fig. 4. Treatment algorithm for palliative systemic therapy
Fig. 4. Treatment algorithm for palliative systemic therapy.HER2 = human epidermal growth factor receptor 2; XP = capecitabine and cisplatin; FP = fluorouracil and cisplatin; IHC = immunohistochemistry. *HER2 IHC 3+ or IHC 2+ and in situ hybridization-positive; †Evaluation of patient performance status, comorbidities, and organ function. Fig. 4. Treatment algorithm for palliative systemic therapy.HER2 = human epidermal growth factor receptor 2; XP = capecitabine and cisplatin; FP = fluorouracil and cisplatin; IHC = immunohistochemistry… J Gastric Cancer Mar;19(1):

Download ppt "Fig. 4. Treatment algorithm for palliative systemic therapy"

Similar presentations

Metastatic Gastric Cancer

Metastatic Gastric Cancer
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
Prepared by Dr. Ammar C. Al-Rikabi & Dr. Ghassan Zidan.

Prepared by Dr. Ammar C. Al-Rikabi & Dr. Ghassan Zidan.
Moving Toward Personalized Treatment for Gastric Cancer: Role of HER2 Testing Frédérique Penault-Llorca, MD, PhD Professor of Pathology Centre Jean Perrin.

Moving Toward Personalized Treatment for Gastric Cancer: Role of HER2 Testing Frédérique Penault-Llorca, MD, PhD Professor of Pathology Centre Jean Perrin.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.

Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.
Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
12 th European Congress on Digital Pathology previously European Congress on Telepathology and international Congress on Virtual Microscopy College des.

12 th European Congress on Digital Pathology previously European Congress on Telepathology and international Congress on Virtual Microscopy College des.
TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR TREATMENT OF HER2- POSITIVE ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION.

TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR TREATMENT OF HER2- POSITIVE ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
Volume 18, Issue 6, Pages (September 2015)

Volume 18, Issue 6, Pages (September 2015)
Volume 34, Pages 122-130 (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.

Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
Novel targets in gastric and esophageal cancer

Novel targets in gastric and esophageal cancer
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Similar presentations

Ads by Google